Leo Fondet 2019 AR2
The report outlines LEO Foundation's activities and financial performance for the fiscal year 2019. As the ultimate owner of LEO Pharma, the Foundation supported international dermatological research by awarding 25 grants and three awards totaling DKK 79 million. LEO Pharma achieved a 4% revenue growth to DKK 10,805 million and made significant progress in its clinical pipeline, notably with tralokinumab. In terms of corporate social responsibility, LEO Pharma worked to reduce its environmental impact, achieving energy savings of 1.2 GWh/year, and developed a stand-alone human rights policy.
Company: Leo Fondet
Sector: Finance & insurance
Country: Denmark
Year: 2019
Type: AR2
Pages: 75
Back to company
Leo Fondet
Annual Report
The report outlines LEO Foundation's activities and financial performance for the fiscal year 2019. As the ultimate owner of LEO Pharma, the Foundation supported international dermatological research by awarding 25 grants and three awards totaling DKK 79 million. LEO Pharma achieved a 4% revenue growth to DKK 10,805 million and made significant progress in its clinical pipeline, notably with tralokinumab. In terms of corporate social responsibility, LEO Pharma worked to reduce its environmental impact, achieving energy savings of 1.2 GWh/year, and developed a stand-alone human rights policy.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees